EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bruceantin and Brusatol: Molecular Insights and Therapeutic Promise of Quassinoids in Cancer Drug Discovery

Shumaila Ijaz, Javed Iqbal iD, Banzeer Ahsan Abbasi, Farishta Zarshan, Tabassum Yaseen, Zakir Ullah iD, Siraj Uddin, Sobia Kanwal, Tariq Mahmood, William N Setzer iD, Javad Sharifi-Rad iD, Daniela Calina iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Shumaila Ijaz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, School of…. Hauptthemen laut MEDLINE: Quassins, Neoplasms, Drug Discovery, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a leading cause of mortality worldwide, with treatment resistance posing a major obstacle to effective therapies. Natural compounds, including quassinoids such as bruceantin and brusatol, derived from Brucea javanica (L.) Merr., have demonstrated potential as novel cancer chemopreventive agents. Bruceantin exhibits cytotoxic effects against diverse cancer cell lines, including leukemia, lymphoma, and myeloma, primarily through inhibition of protein synthesis and induction of apoptosis via caspase and mitochondrial pathways. Similarly, brusatol has shown broad‐spectrum anticancer activities by modulating cellular processes such as apoptosis, cell‐cycle arrest, autophagy, and attenuation of epithelial–mesenchymal transition. Mechanistically, it targets key oncogenic signaling pathways, including PI3K/AKT/mTOR and Keap1/NRF2, and enhances chemosensitivity and radiosensitivity. This review evaluates preclinical findings on the pharmacological properties, mechanisms of action, and anticancer efficacy of bruceantin and brusatol. Their structural modifications, safety profiles, and challenges such as poor bioavailability and systemic toxicity are also explored. Advances in semi‐synthetic derivatives and drug delivery systems are discussed as strategies to enhance therapeutic potential. Comprehensive insights are provided into the molecular and cellular mechanisms underlying their anticancer effects, supported by in vitro and in vivo evidence. Collectively, these findings highlight the promise of bruceantin and brusatol as therapeutic agents and underscore the need for further translational research to optimize their clinical utility. These quassinoids represent a compelling avenue for the development of targeted and adjunctive cancer therapies, potentially overcoming limitations of conventional treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuassinsNeoplasmsDrug DiscoveryAntineoplastic Agents, PhytogenicAntineoplastic AgentsHumansAnimalsApoptosisBruceaMolecular StructureSignal TransductionStructure-Activity Relationship

Stichwörter der Autor:innen

NRF2 pathwayanticancer agentsbruceantinbrusatolchemopreventiononcology

Substanzen

QuassinsbrusatolAntineoplastic Agents, PhytogenicAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Burn and Plastic Surgery, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen…
  • Department of Botany, Bacha Khan University, Charsadda, Khyber Pakhtunkhwa, Pakistan.
  • Department of Botany, Rawalpindi Women University, Rawalpindi, Pakistan.
  • Department of Plant Sciences, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
  • Department of Biology and Environmental Sciences, Allama Iqbal Open University, Islamabad, Pakistan.
  • Aromatic Plant Research Center, Lehi, Utah, USA.

ORCID-Profile: Javed Iqbal, Zakir Ullah, William N Setzer, Javad Sharifi-Rad, Daniela Calina

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Ijaz, S., Iqbal, J., Abbasi, B. A., Zarshan, F., Yaseen, T., Ullah, Z., Uddin, S., Kanwal, S., Mahmood, T., Setzer, W. N., Sharifi-Rad, J., & Calina, D. (2025). Bruceantin and Brusatol: Molecular Insights and Therapeutic Promise of Quassinoids in Cancer Drug Discovery. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70142

Vancouver

Ijaz S, Iqbal J, Abbasi BA, Zarshan F, Yaseen T, Ullah Z, et al. Bruceantin and Brusatol: Molecular Insights and Therapeutic Promise of Quassinoids in Cancer Drug Discovery. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70142

BibTeX
@article{Ijaz2025,
  author = {Ijaz, Shumaila and Iqbal, Javed and Abbasi, Banzeer Ahsan and Zarshan, Farishta and Yaseen, Tabassum and Ullah, Zakir and Uddin, Siraj and Kanwal, Sobia and Mahmood, Tariq and Setzer, William N and Sharifi-Rad, Javad and Calina, Daniela},
  title = {Bruceantin and Brusatol: Molecular Insights and Therapeutic Promise of Quassinoids in Cancer Drug Discovery},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70142}
}
Kostenlos starten →